Premium
Resveratrol treatment promotes titanium implant osseointegration in diabetes mellitus rats
Author(s) -
Hua Yunwei,
Bi Ruiye,
Li Zheru,
Li Yunfeng
Publication year - 2020
Publication title -
journal of orthopaedic research®
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1.041
H-Index - 155
eISSN - 1554-527X
pISSN - 0736-0266
DOI - 10.1002/jor.24651
Subject(s) - osseointegration , implant , resveratrol , medicine , dentistry , diabetes mellitus , endocrinology , surgery , pharmacology
Type II diabetes mellitus (T2DM) is the most common metabolic disorder; it is characterized by hyperglycemia and causes implant failure by influencing implant osseointegration. Resveratrol promotes bone formation, but it is unclear if resveratrol improves implant osseointegration. Thirty 12‐week‐old Sprague‐Dawley rats were divided into control (CTL), diabetes mellitus (DM), and resveratrol treatment (DM + Res) groups. In the DM and DM + Res groups (n = 10 each), T2DM was induced via streptozotocin injections; the remaining 10 rats were considered the CTL group. Eight weeks after the insertion of a rod‐like Ti implant with a 12‐mm length and 1‐mm diameter in the left leg, the rats were euthanized. We analyzed implant osseointegration using microcomputed tomography (micro‐CT), histological analyses, and biomechanical tests. The parameters showed that T2DM negatively influenced implant osseointegration in the tibia. Compared to that in the DM group, the bone loss of peri‐implant bone mass in the DM + Res group was decreased significantly. However, resveratrol still did not induce the same level of implant osseointegration as that observed in the CTL group according to the histological and micro‐CT analyses. These results indicated that resveratrol reduced the influence of DM in implant osseointegration, resulting in increased peri‐implant bone density, improved trabecular architecture, and enhanced biomechanical fixation.